Mots-clés
![]() corticothérapieSynonyme(s)corticoid therapy ;corticosteroid therapy ;thérapie par corticoïdes ;thérapie par corticostéroïdes ;traitement aux cortico-stéroïdes corticotherapy |
Documents disponibles dans cette catégorie (479)

Etendre la recherche sur niveau(x) vers le bas
![]()
Article
![]()
Article
![]()
Article
Brignol TN, Auteur ; Fort PE ; Ventura DF ; Tadayoni R ; Rendon A | 26/09/2018To the Editor: We read with interest the recent article by Rice and colleagues1 reporting on 596 patients with Duchenne muscular dystrophy (DMD) treated with steroid and evaluated for cataract development. The authors reported that the prevalenc[...]![]()
Article
Comment in: Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients. [J AAPOS. 2018] Reply. [J AAPOS. 2018]![]()
Article
Initial Posting: September 5, 2000; Last Update: April 26, 2018. Clinical characteristics. The dystrophinopathies cover a spectrum of X-linked muscle disease ranging from mild to severe that includes Duchenne muscular dystrophy, Becker muscu[...]![]()
Article
Epigenomics Downregulation of miRNA-29, -23 and -21 in urine of Duchenne muscular dystrophy patients
Catapano F, Auteur ; Domingos J ; Perry M ; Ricotti V ; Phillips L ; Servais L ; Seferian A ; Groot I ; Krom YD ; Niks EH ; Verschuuren JJ ; Straub V ; Voit T ; Morgan J ; Muntoni F | 22/03/2018![]()
Article
Leborgne C, Auteur ; Latournerie V ; Boutin S ; Desgue D ; Quéré A ; Pignot E ; Collaud F ; Charles S ; Simon-Sola M ; Masat E ; Jouen F ; Boyer O ; Masurier C ; Mingozzi F ; Veron P | 16/03/2018![]()
Brève
![]()
Article
Schreiber A, Auteur ; Brochard S ; Rippert P ; Fontaine-Carbonnel S ; Payan C ; Poirot I ; Hamroun D ; Vuillerot C | 2018Comment in: Outcome measures in Duchenne muscular dystrophy: sensitivity to change, clinical meaningfulness, and implications for clinical trials. [Dev Med Child Neurol. 2018]![]()
Article
Domingos J, Auteur ; Muntoni F | 2018Comment on: Corticosteroids in Duchenne muscular dystrophy: impact on the motor function measure sensitivity to change and implications for clinical trials. [Dev Med Child Neurol. 2018]![]()
Article
Lancet (London, England), 391, 10119. How glucocorticoids change life in Duchenne muscular dystrophy
Goemans N, Auteur | 2018Comment on: Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. [Lancet. 2018]![]()
Article
McDonald CM, Auteur ; Henricson EK ; Abresch RT ; Duong T ; Joyce NC ; Hu F ; Clemens PR ; Hoffman EP ; Cnaan A ; Gordish-Dressman H | 2018Comment in: How glucocorticoids change life in Duchenne muscular dystrophy. [Lancet. 2018]![]()
Article
Arora H, Auteur ; Willcocks RJ ; Lott DJ ; Harrington AT ; Senesac CR ; Zilke KL ; Daniels MJ ; Xu D ; Tennekoon GI ; Finanger EL ; Russman BS ; Finkel RS ; Triplett WT ; Byrne BJ ; Walter GA ; Sweeney HL ; Vandenborne K | 2018Comment in: Timed function tests have withstood the test of time as clinically meaningful and responsive endpoints in duchenne muscular dystrophy. [Muscle Nerve. 2018]![]()
Article
Birnkrant DJ, Auteur ; Bushby K ; Bann CM ; Apkon SD ; Blackwell A ; Brumbaugh D ; Case L ; Clemens PR ; Hadjiyannakis S ; Pandya S ; Street N ; Tomezsko J ; Wagner KR ; Ward LM ; Weber DR | 2018Comment in: Evidence-based care in Duchenne muscular dystrophy. [Lancet Neurol. 2018]![]()
Article
Russo V, Auteur ; Papa AA ; Williams EA ; Rago A ; Palladino A ; Politano L ; Nigro G | 21/12/2017Comment in: Editorial commentary: Preserving myocardium in muscular dystrophy patients using ACE inhibition. [Trends Cardiovasc Med. 2018]